Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch1 of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is...

BD a leading global medical technology company, and EMS, one of Brazil's leading pharmaceutical companies, announced their collaboration in the launch of a...

Excedr, Inc. a leading provider of full-service laboratory equipment leasing solutions for the life sciences and healthcare industries, announced the closing of $25 million in growth capital. 

InstaMed® Pharmaceuticals, an advanced biotechnology company transforming peptide delivery through its patented InstaRelease® oral dissolving strip platform, announced the appointment of Tracy Gibbs,...

Roche announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas® BV/CV (Bacterial vaginosis/Candida vaginitis) assay. 

Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the...

Virax Biolabs Group Limited a biotechnology company focused on immune response detection, T cell immune profiling and in vitro diagnostic technologies, today published a shareholder update from Chief...

A multidisciplinary team at Children's Hospital of Philadelphia (CHOP) substantially increased naloxone co-prescribing for patients prescribed outpatient opioid prescriptions through an...

Hologic, Inc. announced that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima...

Merck, a leading global science and technology company, announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26,...

BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) for full...

On July 2, 2026, the U.S. Food and Drug Administration (FDA) approved the use of wilate® (von Willebrand Factor/Coagulation Factor VIII Complex [Human]) for routine prophylaxis to reduce the...